Study of two medicines for relapsed T-PLL or NHL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests APG-115 alone or with APG-2575 in adults whose T-PLL or NHL has come back or did not respond to treatment. It may help by targeting the cancer cells with a new drug approach when standard therapies have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 years or older.
- You have T-PLL that has returned or not responded, or you have a confirmed NHL that is relapsed, refractory, or can’t be treated with known helpful therapies.
- You’ve had no chemotherapy or antibody therapy in the 7 days before starting study drugs (some fast-growing cases may use steroids or hydroxyurea until 24 hours before).
- Blood counts and organ health must be adequate (neutrophils, hemoglobin, and platelets must meet minimums).
- You’re well enough to function day-to-day (ECOG score 0–2).
- You can understand the study and sign consent (or your legal representative can).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (cladribine, ruxolitinib, and venetoclax) for people with T-cell prolymphocytic leukemia (T-PLL) that has come back or stopped responding to prior treatment. The goal is to see if this therapy can help control the disease.
This trial studies APG-2575 in people with CLL/SLL that has come back or is not responding to prior treatments. It may help shrink disease and improve control when standard options have stopped working.
This Phase 1/2 study tests APG2575 alone or combined with other treatment in people whose CLL/SLL has come back or did not respond to prior therapy. The goal is to see how well the treatment works and how safe it is.
This Phase 1 study tests APG-115 alone or with azacitidine or cytarabine in people whose acute myeloid leukemia (AML) or high-risk MDS has come back or hasn’t responded. The goal is to see safety and whether the treatment can work for these conditions.
This study tests two experimental drugs for people with neuroblastoma or other solid tumors that have not responded to standard treatment. APG-115 is given alone or with APG-2575 to see if it can shrink tumors and help patients feel better.
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
Hear when a new T-Prolymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.